Louisiana is poised to hike its sports betting tax to help colleges pay their athletes
Legislation pending before Gov. Jeff Landry would make Louisiana the first state to raise taxes to fund college sports since a judge approved a landmark settlement with the NCAA allowing schools to directly pay athletes for use of their name, image and likeness (NIL). Anticipating the court's approval, Arkansas this year became the first to waive state income taxes on NIL payments made to athletes by higher education institutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Raducanu and Fernandez beat the heat to reach DC Open semis
Britain's Emma Raducanu reached the brink of her first WTA final since winning the 2021 US Open, ousting Greece's Maria Sakkari 6-4, 7-5 on Friday at the DC Open. And the woman she defeated four years ago in that Flushing Meadows championship match, Canada's Leylah Fernandez, could be her opponent for the Washington hard court crown. Raducanu, who missed most of 2023 after hand and ankle surgery and part of last year with a left foot injury, reached her first WTA semi-final since last year at Nottingham by dispatching Sakkari in sweltering conditions of 95F (35C). "It was one of the toughest matches conditions-wise I've ever played in," Raducanu said. "Those points in the second set, I was getting a bit wobbly I'm just happy I could close it out and it was two sets. "I think the humidity here, as well, it just makes it feel completely like you have just opened an oven and it just stayed open and your head is in there. That's how it feels." Raducanu, in her only tour-level final, won the 2021 US Open as a teen qualifier over teen Fernandez, who advanced to the DC Open semi-finals by battling through leg cramps in the second set and saving a set point to oust American Taylor Townsend 6-4, 7-6 (7/4). Left-hander Fernandez will next face the winner of a later match between third seed Elena Rybakina of Kazakhstan and Polish fifth seed Magdalena Frech. In Saturday's other semi-final, Raducanu will face the later winner between Danish fourth seed Clara Tauson and Anna Kalinskaya. Raducanu, Britain's first women's Grand Slam singles champion since Virginia Wade in 1977 at Wimbledon, beat four-time Grand Slam champion Naomi Osaka in the second round before downing Sakkari in the quarter-finals, but not before a medical timeout in the second set. "Brutal conditions. Right in the peak heat of the day. It was incredibly difficult," Raducanu said. "I had to call a doctor on. Wasn't feeling too good in the second set. "When it's at that stage you know you're going to suffer and you have to just go until you physically can't anymore. It could be a little dangerous but you just leave it all out there on the court as an athlete." Raducanu rallied to win the final five games of the match. "You get to a point where you're so tired that you don't really know what you're doing anymore, and I think maybe that helped," Raducanu said. "I just really had to be smooth and conserve energy.... You just have to really be so focused." - 'Big benchmark' - Raducanu said reaching the semis was a "big benchmark" after years of injury. "I have played three great matches to be here in the semifinals, and it is the first semis in a long time," she said. "I'm really proud of that and just happy that all the hard work I've been doing is starting to pay off." Fernandez surrendered a break with a double fault to trail Townsend 3-4 in the second set and despite leg cramps broke the American on her eighth opportunity in the 10th game to level matters at 5-5 on the way to the tie-breaker. Fernandez has won three WTA titles, the 2021 and 2022 Monterrey Opens and the 2023 Hong Kong Open. Her most recent final was last year at Eastbourne. js/rcw
Yahoo
8 minutes ago
- Yahoo
Cedric Tillman injures leg at Browns practice
Browns wide receiver Cedric Tillman had to leave Friday's practice with an injury. Reporters at the session noted that Tillman went down after jumping to try for a high pass from Joe Flacco in the end zone at training camp. Tillman left the field with trainers after the play and did not return. The Browns said, via Mary Kay Cabot of that Tillman suffered a lower left leg injury. They did not share any other details about the injury or how it would impact Tillman's availability for future practices. Tillman was a 2023 third-round pick in Cleveland. He had 50 catches for 563 yards and three touchdowns in his first two seasons.
Yahoo
8 minutes ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
